66. Gill, P. S., et al., “Azidothymidine Associated with Bone Marrow Failure in the Acquired Immunodeficiency Syndrome (AIDS),” Annals of Internal Medicine, 107 (1987), pp. 502-505.

- Kolata, G., “Imminent Marketing of AZT Raises Problems: Marrow Suppression Hampers AZT Use in AIDS Victims,” Science, 235 (1987), pp. 1462-1463.

- Balzarini, J., et al., “Differential Patterns of Intracellular Metabolism of 2',3'-didehydro- 2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, Two Potent Anti-Human Immunodeficiency Virus Compounds,” Journal of Biological Chemistry, 264 (1989), pp. 6127-6133.

- Mansuri, M. M., et al., “Comparison of In Vitro Biological Properties and Mouse Toxicities of Three Thymidine Analogs Active Against Human Immunodeficiency Virus,” Antimicrobial Agents in Chemotherapy, 34 (1990), pp. 637-641.

- Hitchcock, M. J. M., “Review: Antiviral Portrait Series, Number 1; 2',3'-didehydro-2',3'- dideoxythymidine (D4T), and Anti-HIV Agent,” Antiviral Chemistry in Chemotherapy, 2 (1991), pp. 125-132.